Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
“Postprandial glucose area under the curve was significantly reduced [-436 mmol x min/liter ( saxagliptin 2.5 mg plus TZD) and -514 mmol x min/liter (saxagliptin 5 mg plus TZD) vs. -149 mmol x min/liter (PBO)].”
The Journal of clinical endocrinology and metabolism • 2009 | View Paper
“ ResultsSaxagliptin treatment inhibited DPP4 activity by more than 90% and increased GLP-1 levels four-fold following a 2 g/kg glucose load , but did not affect fasting GLP-1 levels.”